Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001074813 | SCV001240411 | pathogenic | Retinal dystrophy | 2019-07-11 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001253657 | SCV001429492 | pathogenic | Cone-rod synaptic disorder, congenital nonprogressive | 2018-02-14 | criteria provided, single submitter | clinical testing | This variant was identified as homozygous |
Labcorp Genetics |
RCV001385530 | SCV001585413 | pathogenic | not provided | 2020-07-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg225*) in the CABP4 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs531851447, ExAC 0.007%). This variant has been observed in individual(s) with cone-rod synaptic disorder (PMID: 28041643, 28341476, 29525873). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 438047). Loss-of-function variants in CABP4 are known to be pathogenic (PMID: 25307992). For these reasons, this variant has been classified as Pathogenic. |
NIHR Bioresource Rare Diseases, |
RCV000504725 | SCV000598872 | likely pathogenic | Cone dystrophy | 2015-01-01 | no assertion criteria provided | research | |
Genomics England Pilot Project, |
RCV001253657 | SCV001760280 | pathogenic | Cone-rod synaptic disorder, congenital nonprogressive | no assertion criteria provided | clinical testing |